Arthropathy is an unusual but significant complication of mumps viral infection. Predominantly affecting young adult males, large and small joint involvement occur before, after, or in the absence of parotitis. Fever, leukocytosis, and elevated erythrocyte sedimentation rate accompany an occasionally protracted course. A high incidence of associated visceral manifestations occurs among patients with mumps arthritis. A review of the pathogenesis of these other complications suggests direct viral invasion as the most likely pathogenesis of mumps arthritis. The possibility of mumps virus arthritis should be considered in patients with acute-onset, obscure, or febrile seronegative arthritis.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1093/clinids/6.3.338 | DOI Listing |
Clin Rheumatol
January 2025
Department of Pediatric Rheumatology, Zeynep Kamil Women and Children's Diseases Training and Research Hospital, Istanbul, Turkey.
Rheumatol Int
December 2024
Infectious Diseases, Immunology and Rheumatology Unit, Second Department of Pediatrics, ''P. & A. Kiriakou" Children's Hospital, Athens Medical School, National and Kapodistrian University of Athens (NKUA), Athens, Greece.
Novel treatments have revolutionized the care and outcome of patients with juvenile idiopathic arthritis (JIA). Patients with rheumatic diseases are susceptible to infections, including vaccine preventable ones, due to waning immunity, failing immune system and immunosuppressive treatment received. However, data regarding long-term immunological memory and response to specific vaccines are limited.
View Article and Find Full Text PDFVaccine
August 2023
Department of Pediatric Immunology and Rheumatology, Wilhelmina Children's Hospital, University Medical Center Utrecht, Utrecht, the Netherlands.
Introduction: Vaccines, especially live attenuated vaccines, in children with JIA pose a great challenge due to both potential lower immunogenicity and safety as a result of immunosuppressive treatment. For many years, in the Netherlands, JIA patients receive a measles-mumps-rubella (MMR) booster vaccine at the age of nine years as part of the national immunization program.
Objectives: To study long-term humoral immunoprotection in a large cohort of JIA patients who received the MMR booster vaccine while being treated with immunomodulatory therapies at the Wilhelmina Children's Hospital in Utrecht, the Netherlands.
Vaccine
May 2023
Department of Paediatric Immunology and Rheumatology, Wilhelmina Children's Hospital, University Medical Center Utrecht, Utrecht, the Netherlands.
Objectives: To study short and long-term disease activity and vaccine-related adverse events in a cohort of JIA patients who received the live attenuated measles-mumps-rubella (MMR) booster vaccine while being treated with immunosuppressive and immunomodulatory therapies.
Methods: A retrospective study was performed in the UMC Utrecht, clinical and therapeutic data were collected from electronic medical records for two visits before and two visits after the MMR booster vaccine of JIA patients. Drug therapy was collected and adverse events related to the vaccine were requested from the patients during clinical visits or by short phone interviews.
Cureus
December 2022
Internal Medicine, Rajah Muthiah Medical College & Hospital, Chidambaram, IND.
Mumps is an acute viral illness occurring in children and young adults transmitted via droplets. It is a vaccine-preventable illness caused by the mumps virus, an RNA (ribonucleic acid) virus belonging to theParamyxoviridaefamily. It typically presents with fever, parotitis, epididymo-orchitis, oophoritis, meningitis, encephalitis, pancreatitis and arthritis.
View Article and Find Full Text PDFEnter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!